Skip to content

ADMA Biologics ADMA EPS (Diluted)

EPS (Diluted) at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$0.14+6.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1.84-43.8%
Zymeworks logo
ZymeworksZYME
-$0.59-96.7%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
-$19.55-954%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$1.06-11.6%
Quest Diagnostics logo
Quest DiagnosticsDGX
$2.24+15.5%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's EPS (diluted)?
ADMA Biologics (ADMA) reported EPS (diluted) of $0.19 in Q1 2026.
How has ADMA Biologics's EPS (diluted) changed year-over-year?
ADMA Biologics's EPS (diluted) increased by 72.7% year-over-year, from $0.11 to $0.19.
What is the long-term trend for ADMA Biologics's EPS (diluted)?
Over 4 years (2021 to 2025), ADMA Biologics's EPS (diluted) has grown at a 4.1% compound annual growth rate (CAGR), from -$0.51 to $0.60.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.